Editor's Correspondence
October 26, 2009

ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Intern Med. 2009;169(19):1806-1818. doi:10.1001/archinternmed.2009.371

I read with interest and curiosity the recent revisitation of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial by Wright et al.1 They concluded that current evidence confirmed that neither α-blockers, angiotensin-converting enzyme inhibitors (ACEIs), nor calcium channel blockers (CCBs), surpass thiazide-type diuretics (at an appropriate dosage) as initial therapy for reduction of cardiovascular or renal risk.1 We cannot agree more, especially in light of recent trials including the ONTARGET trial2 and new insights into plausible benefits of cardioprotection and renoprotection using different antihypertensive classes.3,4

First Page Preview View Large
First page PDF preview
First page PDF preview